|Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer|
M Capello, LE Bantis, G Scelo, Y Zhao, P Li, DS Dhillon, NJ Patel, ...
JNCI: Journal of the National Cancer Institute 109 (4), 2017
|A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer|
JF Fahrmann, LE Bantis, M Capello, G Scelo, JB Dennison, N Patel, ...
JNCI: Journal of the National Cancer Institute 111 (4), 372-379, 2019
|Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity|
M Capello, JV Vykoukal, H Katayama, LE Bantis, H Wang, DL Kundnani, ...
Nature communications 10 (1), 1-13, 2019
|Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins|
F Guida, N Sun, LE Bantis, DC Muller, P Li, A Taguchi, D Dhillon, ...
JAMA oncology 4 (10), e182078-e182078, 2018
|Testing the gene expression classification of the EMT spectrum|
D Jia, JT George, SC Tripathi, DL Kundnani, M Lu, SM Hanash, ...
Physical biology 16 (2), 025002, 2019
|NFATc acts as a non-canonical phenotypic stability factor for a hybrid epithelial/mesenchymal phenotype|
AR Subbalakshmi, D Kundnani, K Biswas, A Ghosh, S Hanash, ...
|CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes|
M Capello, JF Fahrmann, MV Rios Perez, JV Vykoukal, E Irajizad, ...
JCO Precision Oncology 4, 426-436, 2020
|Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis|
M Kobayashi, H Katayama, E Irajizad, JV Vykoukal, JF Fahrmann, ...
Cancers 12 (2), 485, 2020